Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.

RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.

The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.

Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.

So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.

The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?

Pfizer moves to take PF-07934040 into its first clinical trial.

The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.